MDGL vs NAMS Stock Comparison

MDGL currently leads NAMS in this stock comparison, with AIQ scores of 57 vs 41. The clearest difference is value.

Market data as of Nov 15, 2026 market close· AIQ score gap 16 points
MDGL
Healthcare
vs
NAMS
Healthcare
MDGL
Madrigal Pharmaceuticals, Inc.
Leads
Price
$427
Day move
+0.51%
AIQ Score
57/100
Best edge
Value
Sector
Healthcare
NAMS
NewAmsterdam Pharma Company N.V.
Price
$20.14
Day move
+0.85%
AIQ Score
41/100
Best edge
Balanced
Sector
Healthcare

What is the main difference between MDGL and NAMS?

MDGL leads the current stock comparison as Madrigal Pharmaceuticals, Inc., with the clearest separation coming from value and the broader AIQ evidence mix.

AlgovestIQ AIQ Comparison

Madrigal Pharmaceuticals, Inc. vs NewAmsterdam Pharma Company N.V.

Data as of Nov 15, 2026· market close· Healthcare· Coverage 64/66 fields· High confidence
AIQ VerdictStableAIQ Comparison Conviction 9/10

MDGL leads

MDGL leads by 16 AIQ points, primarily on Value and Momentum, but the lead has narrowed from 23 points over 30 sessions. Wall Street currently favors NAMS on target upside.

Stable: 5 of 6 evidence groups support MDGL, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 5 of 6Comparison trend: Weakening
MDGL

Madrigal Pharmaceuticals, Inc.

Leads
AIQ Score
57/100
AIQ Edge Score
6/10
NAMS

NewAmsterdam Pharma Company N.V.

AIQ Score
41/100
AIQ Edge Score
2/10

The Algovestiq AIQ Score currently favors MDGL over NAMS, 57 versus 41 as of Nov 15, 2026. MDGL's advantage is driven primarily by stronger value and momentum. MDGL also shows the weaker technical structure relative to its 50-day moving average, though analyst target upside currently favors NAMS. 5 of 6 covered evidence groups favor MDGL today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. MDGL lead: Weakening — the AIQ differential moved from 23 to 16 points over 30 sessions. MDGL leads on all four AIQ factor dimensions. Value is itself one of those four, so a sweep is not explained by valuation alone — it deserves additional scrutiny for unmodeled catalysts, expectations or event risk.

Compare Madrigal Pharmaceuticals, Inc. and NewAmsterdam Pharma Company N.V. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

Currently unavailable

Performance over time

Price return from daily closes; distributions are not included.

MDGL
+546.8%
NAMS
+94.6%

Price return comparison

Growth of $10,000, price only

MDGL $64,678 · NAMS $19,459

Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.

Compare MDGL and NAMS against another ticker

Open a multi-ticker workspace without changing this focused pair page.

Basic: 2 symbols·Explorer: 3 symbols·Pro and Premium: 5 symbols·Your limit: 2

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

MDGL advantage
0
NAMS advantage
  • Value66 vs 42
    MDGL +24
  • Momentum40 vs 22
    MDGL +18
  • Risk Resilience63 vs 48
    MDGL +15
  • Quality67 vs 58
    MDGL +9

5 of 6 evidence groups favor MDGL. MDGL’s edge is concentrated in value and momentum.

What changed since the last close

Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.

MDGL0 AIQ

Largest factor move: Momentum -1, not enough on its own to move the overall score.

New signals

  • ADX Trend Weakening — neutral, trend, medium horizon
  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.0%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
NAMS0 AIQ

Largest factor move: Value +2, not enough on its own to move the overall score.

No signal started or stopped since the prior session; its 6 active signals are unchanged.

MDGL's lead was unchanged in the latest session.

Deeper signal detail for each name lives on its own signals page — MDGL and NAMS both carry a full feed there.

The central trade-off

MDGL (Madrigal Pharmaceuticals, Inc.): the stronger current systematic profile, led by value and momentum.

NAMS (NewAmsterdam Pharma Company N.V.): the counter-case, on analyst expectations — but at materially higher volatility, 69.8% against 49.9%.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

MDGL

MDGL on the overall AIQ Score, which weights Quality and Value most heavily.

Growth

MDGL

MDGL on combined revenue and EPS growth.

Value

MDGL

MDGL on the peer-relative Value factor, by 24 points.

Momentum

MDGL

MDGL on the Momentum factor, by 18 points.

Lower downside

MDGL

MDGL on Risk Resilience, by 15 points.

Analyst upside

NAMS

NAMS on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors MDGL, analyst targets favor NAMS. That disagreement is the most useful thing on this page.

MeasureMDGLNAMSNote
Implied upside to target+54.5%+202.9%NAMS has more room
Target dispersion+30.6%0%Lower is tighter analyst agreement
ConsensusBuyBuyContext, not a primary driver
Analysts covering1916Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

5 of 6 covered evidence groups favor MDGL. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScoreMDGL57 vs 41
FundamentalsMDGLon balancerevenue growth 18.4% vs 4.2%; EPS growth 195.5% vs 73.1%; TTM ROE 8.8% vs -2.8%; gross margin 91% vs 97.8%; operating margin -10.7% vs -9% — MDGL takes 3 of 5 decided legs, not all of them
ValuationMDGLValue 66 vs 42
TechnicalsMDGLPrice vs 50-day -10.2% vs -6.4%; vs 200-day -13.8% vs -30.9%
Risk ResilienceMDGLRisk Resilience 63 vs 48
Analyst expectationsNAMSTarget upside 54.5% vs 202.9%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MDGL and NAMS and are excluded from the count.

AIQ Decision Stability

Stable

The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.

  • The AIQ gap is wide at 16 points. (supports the conclusion holding)
  • 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The lead has been steady session to session. (supports the conclusion holding)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MDGL.

How the comparison changed

120 daily snapshots · May 27 – Nov 13

MDGL lead: Weakening — the AIQ differential moved from 23 to 16 points over 30 sessions.

May 27MDGL leads above the line · NAMS leads belowNov 13
Today
MDGL +16
57 vs 41
7 sessions ago
MDGL +18
57 vs 39
30 sessions ago
MDGL +23
57 vs 34
90 sessions ago
MDGL +20
60 vs 40

The lead has not changed hands in this window.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

MDGLConflicted

3 bullish / 2 bearish / 2 neutral, conflicted

Only MDGL

  • OBV Bullish Divergence — bullish, volume, medium horizon (-5.0%)
  • RSI Bullish Divergence — bullish, momentum, medium horizon
NAMSConflicted

1 bullish / 3 bearish / 2 neutral, conflicted

Only NAMS

  • Beta Spike Warning — bearish, risk_regime, long horizon

Both carry 5 more signals that do not separate them: Death Cross Active, ADX Trend Weakening, ATR Expansion - Breakout Mode, Downtrend Structure Active, MACD Histogram Expanding Bullish.

MDGL leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

MDGLNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.51%, AIQ 0 points).

NAMSNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +0.85%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1NAMS closes the Value gap — currently 24 points behind, the largest single contributor to MDGL's edge.
  2. 2NAMS's Death Cross Active resolves — a bearish trend rule currently active against it.
  3. 3MDGL's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 16-point move would eliminate MDGL's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

MDGL leads on balance
MetricMDGLNAMS
Revenue growth (YoY)18.4%4.2%
EPS growth (YoY)195.5%73.1%
Gross margin91%97.8%
Operating margin-10.7%-9%
Return on equity (TTM)8.8%-2.8%
Debt to equity0.560

Performance

MDGL leads 5 of 6 windows
MetricMDGLNAMS
1 week (5 sessions)6.9%6.6%
1 month (20 sessions)-5%1.6%
3 months (63 sessions)-18.6%-25.1%
6 months (126 sessions)-18.4%-43.2%
Year to date-26.6%-42.6%
1 year (252 sessions)-19.2%-47.4%

Technicals

MDGL has the stronger structure
MetricMDGLNAMS
RSI (14)42.547.3
ADX (14)24.816.7
Price vs 50-day-10.2%-6.4%
Price vs 200-day-13.8%-30.9%
Volatility (1M, annualized)49.9%69.8%

Risk

MDGL is the more resilient
MetricMDGLNAMS
Beta0.411.43
Sharpe ratio-0.32-0.91
Sortino ratio-0.46-1.25
Max drawdown-34.3%-54.4%
Current drawdown-29.1%-51.4%
Annualized volatility42.6%53.8%
Value at risk (95%)-4.1%-5.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, MDGL or NAMS?

On the Algovestiq AIQ Score, MDGL is the stronger of the two as of Nov 15, 2026, scoring 57 against NAMS's 41. The edge comes from value and momentum. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is MDGL or NAMS the better buy right now?

MDGL carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.

Why does the AIQ Score favor MDGL over NAMS?

The composite weights Quality, Value, Momentum and Risk Resilience. MDGL leads Value by 24 points; MDGL leads Momentum by 18 points; MDGL leads Risk Resilience by 15 points. MDGL leads on all four AIQ factor dimensions. Value is itself one of those four, so the sweep is not explained by NAMS simply being cheaper — it warrants extra scrutiny for unmodeled catalysts, forward expectations or event risk the factors do not capture.

Which has more analyst upside, MDGL or NAMS?

Analyst price targets imply +54.5% upside for MDGL and +202.9% for NAMS, so the Street currently favors NAMS. That points the opposite way to the AIQ Score, which favors MDGL. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, MDGL or NAMS?

MDGL is the better-valued of the two on the peer-relative Value factor. MDGL on the peer-relative Value factor, by 24 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, MDGL or NAMS?

MDGL on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, MDGL or NAMS?

MDGL on the Momentum factor, by 18 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, MDGL or NAMS?

MDGL is the more resilient of the two, so the other name carries the higher downside risk. MDGL on Risk Resilience, by 15 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is MDGL more profitable than NAMS?

The profitability evidence is mixed: gross margin 91% vs 97.8%; operating margin -10.7% vs -9%; ttm roe 8.8% vs -2.8%. MDGL leads on one measure and NAMS on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is MDGL's lead over NAMS getting stronger or weaker?

MDGL lead: Weakening — the AIQ differential moved from 23 to 16 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.

What would change the MDGL vs NAMS verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: NAMS closes the Value gap — currently 24 points behind, the largest single contributor to MDGL's edge; NAMS's Death Cross Active resolves — a bearish trend rule currently active against it; MDGL's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; the narrowing continues — the lead has already given back 7 points over 30 sessions, and a further 16-point move would eliminate MDGL's advantage entirely.

What do the current signals say about MDGL and NAMS?

MDGL: 3 bullish / 2 bearish / 2 neutral, conflicted. NAMS: 1 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MDGL is Death Cross Active (bearish, long horizon). On NAMS it is Death Cross Active (bearish, long horizon).

Compare MDGL and NAMS with others

Continue your research

This page answers which of the two. These answer the questions on either side of it.

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.